Current advancements in promoting remyelination in multiple sclerosis
David Kremer, Rainer Akkermann, Patrick Küry and Ranjan Dutta
Abstract: Current multiple sclerosis (MS) therapies are effective in reducing relapse rate, short-term measures of disability, and magnetic resonance imaging (MRI) measures of inflammation in relapsing remitting MS (RRMS), whereas in progressive/degenerative disease phases these medications are of little or no benefit. Therefore, the development of new therapies aimed at reversing neurodegeneration is of great interest. Remyelination, which is usually a spontaneous endogenous process, is achieved when myelinproducing oligodendrocytes are generated from oligodendrocyte precursor cells (OPCs). Even though these precursor cells are abundant in MS brains, their regeneration capacity is limited. Enhancing the generation of myelin-producing cells is therefore a major focus of MS research. Here we present an overview of the different advancements in the field of remyelination, including suitable animal models for testing remyelination therapies, approved medications with a proposed role in regeneration, myelin repair treatments under investigation in clinical trials, as well as future therapeutics aimed at facilitating myelin repair.
The full paper is available at the following link.Search criteria:
Online literature search for this review was performed with pubmed.com and scholar.google.com using parameters such as the respective drug or compound name in conjunction with the keywords “neural stem cell,” “oligodendroglia,” “oligodendroglial precursor cell,” “myelin,” and “remyelination.” The clinical trials discussed in this review were checked for their current status on clinicaltrials.gov.
https://journals.sagepub.com/doi/pdf/10 ... 8518800827